Acumen Pharmaceuticals entered into a Securities Purchase Agreement to sell 10,833,331 shares of common stock at $3.30 per share to institutional accredited investors in a private placement expected to yield $35.75 million gross proceeds, primarily for its Enhanced Brain Delivery program. The shares are unregistered under Section 4(a)(2) of the Securities Act, with a Registration Rights Agreement providing for resale registration.
Key takeaways
Entered Securities Purchase Agreement on March 13, 2026, to sell 10,833,331 shares at $3.30/share for ~$35.75M gross proceeds.
Private placement expected to close March 16, 2026, subject to customary conditions.
Net proceeds to support Enhanced Brain Delivery (EBD) program, including preclinical work for lead clinical candidate nomination, working capital.
Registration Rights Agreement requires resale registration statement filing within 2 business days after 2025 Form 10-K.
Issued press release and updated corporate presentation on EBD preclinical data showing 14-40x brain penetration in NHPs.
Shares issued exempt from registration under Section 4(a)(2); no general solicitation.